KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:PHI1 • NL0000009538

24.83 EUR
+0.67 (+2.77%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

Taking everything into account, PHI1 scores 3 out of 10 in our fundamental rating. PHI1 was compared to 68 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of PHI1 have multiple concerns. PHI1 is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year PHI1 was profitable.
  • In the past year PHI1 had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
  • PHI1 had a positive operating cash flow in 4 of the past 5 years.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

1.2 Ratios

  • PHI1's Return On Assets of 0.63% is on the low side compared to the rest of the industry. PHI1 is outperformed by 63.24% of its industry peers.
  • PHI1 has a Return On Equity of 1.56%. This is in the lower half of the industry: PHI1 underperforms 63.24% of its industry peers.
  • PHI1's Return On Invested Capital of 3.95% is on the low side compared to the rest of the industry. PHI1 is outperformed by 64.71% of its industry peers.
Industry RankSector Rank
ROA 0.63%
ROE 1.56%
ROIC 3.95%
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • With a Profit Margin value of 0.93%, PHI1 is not doing good in the industry: 63.24% of the companies in the same industry are doing better.
  • PHI1's Operating Margin of 6.10% is on the low side compared to the rest of the industry. PHI1 is outperformed by 60.29% of its industry peers.
  • In the last couple of years the Operating Margin of PHI1 has declined.
  • The Gross Margin of PHI1 (43.49%) is worse than 73.53% of its industry peers.
  • PHI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.1%
PM (TTM) 0.93%
GM 43.49%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHI1 is destroying value.
  • The number of shares outstanding for PHI1 has been reduced compared to 1 year ago.
  • Compared to 5 years ago, PHI1 has more shares outstanding
  • Compared to 1 year ago, PHI1 has a worse debt to assets ratio.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • PHI1 has an Altman-Z score of 1.97. This is not the best score and indicates that PHI1 is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a Altman-Z score value of 1.97, PHI1 is not doing good in the industry: 60.29% of the companies in the same industry are doing better.
  • PHI1 has a debt to FCF ratio of 14.51. This is a negative value and a sign of low solvency as PHI1 would need 14.51 years to pay back of all of its debts.
  • The Debt to FCF ratio of PHI1 (14.51) is worse than 63.24% of its industry peers.
  • PHI1 has a Debt/Equity ratio of 0.69. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
  • The Debt to Equity ratio of PHI1 (0.69) is worse than 72.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 14.51
Altman-Z 1.97
ROIC/WACC0.6
WACC6.62%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

2.3 Liquidity

  • PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.32, PHI1 is not doing good in the industry: 61.76% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.86 indicates that PHI1 may have some problems paying its short term obligations.
  • PHI1's Quick ratio of 0.86 is on the low side compared to the rest of the industry. PHI1 is outperformed by 67.65% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.86
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • PHI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.15%, which is quite good.
  • The Earnings Per Share has been decreasing by -7.17% on average over the past years.
  • Looking at the last year, PHI1 shows a decrease in Revenue. The Revenue has decreased by -1.43% in the last year.
  • Measured over the past years, PHI1 shows a small growth in Revenue. The Revenue has been growing by 1.00% on average per year.
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
Revenue 1Y (TTM)-1.43%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%

3.2 Future

  • PHI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.28% yearly.
  • Based on estimates for the next years, PHI1 will show a small growth in Revenue. The Revenue will grow by 3.00% on average per year.
EPS Next Y4.94%
EPS Next 2Y4.81%
EPS Next 3Y7.44%
EPS Next 5Y10.28%
Revenue Next Year-2.27%
Revenue Next 2Y0.25%
Revenue Next 3Y1.58%
Revenue Next 5Y3%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 16.78 indicates a correct valuation of PHI1.
  • Based on the Price/Earnings ratio, PHI1 is valued cheaply inside the industry as 92.65% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of PHI1 to the average of the S&P500 Index (27.92), we can say PHI1 is valued slightly cheaper.
  • The Price/Forward Earnings ratio is 16.32, which indicates a correct valuation of PHI1.
  • Based on the Price/Forward Earnings ratio, PHI1 is valued a bit cheaper than 73.53% of the companies in the same industry.
  • PHI1's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.78.
Industry RankSector Rank
PE 16.78
Fwd PE 16.32
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHI1 is valued a bit cheaper than the industry average as 69.12% of the companies are valued more expensively.
  • PHI1's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 41.37
EV/EBITDA 12.79
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)3.39
PEG (5Y)N/A
EPS Next 2Y4.81%
EPS Next 3Y7.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PHI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KONINKLIJKE PHILIPS NV

FRA:PHI1 (2/6/2026, 7:00:00 PM)

24.83

+0.67 (+2.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04
Earnings (Next)02-10
Inst Owners44.83%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap23.91B
Revenue(TTM)17.78B
Net Income(TTM)165.00M
Analysts72.14
Price Target27.26 (9.79%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP199.39%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.57%
Min EPS beat(2)14.1%
Max EPS beat(2)31.04%
EPS beat(4)3
Avg EPS beat(4)13.85%
Min EPS beat(4)-11.97%
Max EPS beat(4)31.04%
EPS beat(8)3
Avg EPS beat(8)-0.89%
EPS beat(12)6
Avg EPS beat(12)18.79%
EPS beat(16)6
Avg EPS beat(16)4.51%
Revenue beat(2)0
Avg Revenue beat(2)-2.19%
Min Revenue beat(2)-2.4%
Max Revenue beat(2)-1.97%
Revenue beat(4)0
Avg Revenue beat(4)-2.34%
Min Revenue beat(4)-3.04%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-3.43%
Revenue beat(12)2
Avg Revenue beat(12)-1.64%
Revenue beat(16)2
Avg Revenue beat(16)-1.76%
PT rev (1m)-2.2%
PT rev (3m)-1.72%
EPS NQ rev (1m)1.37%
EPS NQ rev (3m)5.07%
EPS NY rev (1m)0.57%
EPS NY rev (3m)4.51%
Revenue NQ rev (1m)-0.52%
Revenue NQ rev (3m)-0.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.45%
Valuation
Industry RankSector Rank
PE 16.78
Fwd PE 16.32
P/S 1.34
P/FCF 41.37
P/OCF 19.49
P/B 2.27
P/tB N/A
EV/EBITDA 12.79
EPS(TTM)1.48
EY5.96%
EPS(NY)1.52
Fwd EY6.13%
FCF(TTM)0.6
FCFY2.42%
OCF(TTM)1.27
OCFY5.13%
SpS18.47
BVpS10.96
TBVpS-1.42
PEG (NY)3.39
PEG (5Y)N/A
Graham Number19.1
Profitability
Industry RankSector Rank
ROA 0.63%
ROE 1.56%
ROCE 5.61%
ROIC 3.95%
ROICexc 3.95%
ROICexgc 10.33%
OM 6.1%
PM (TTM) 0.93%
GM 43.49%
FCFM 3.25%
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y10.6%
ROICexgc growth 5Y-2.51%
ROICexc growth 3Y4.73%
ROICexc growth 5Y-6.98%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-ScoreN/A
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 14.51
Debt/EBITDA 2.93
Cap/Depr 46.69%
Cap/Sales 3.65%
Interest Coverage 250
Cash Conversion 49.6%
Profit Quality 350.3%
Current Ratio 1.32
Quick Ratio 0.86
Altman-Z 1.97
F-ScoreN/A
WACC6.62%
ROIC/WACC0.6
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
EPS Next Y4.94%
EPS Next 2Y4.81%
EPS Next 3Y7.44%
EPS Next 5Y10.28%
Revenue 1Y (TTM)-1.43%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%
Revenue Next Year-2.27%
Revenue Next 2Y0.25%
Revenue Next 3Y1.58%
Revenue Next 5Y3%
EBIT growth 1Y712.43%
EBIT growth 3Y0.03%
EBIT growth 5Y-7.17%
EBIT Next Year48.95%
EBIT Next 3Y19.49%
EBIT Next 5Y15.13%
FCF growth 1Y-45.51%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y-31.12%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%

KONINKLIJKE PHILIPS NV / PHI1.DE FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


How profitable is KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 2 / 10.


How financially healthy is KONINKLIJKE PHILIPS NV?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 2 / 10.


Can you provide the dividend sustainability for PHI1 stock?

The dividend rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 0 / 10 and the dividend payout ratio is 199.39%.